Tolerability of Dose Escalation of Ibandronate in Patients with Multiple Myeloma and End-Stage Renal Disease: A Case Series

Publisher： Karger

E-ISSN： 2296-5262|32|8-9|482-486

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.32, Iss.8-9, 2009-07, pp. : 482-486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox in thalassemia patients with end‐stage renal disease

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 91, Iss. 10, 2016-10 ,pp. : E456-E457

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ibandronate for the Treatment of Hypercalcemia or Nephrocalcinosis in Patients with Multiple Myeloma and Acute Renal Failure: Case Reports

By  

Acta Haematologica, Vol. 116, Iss. 3, 2006-10 ,pp. : 165-172

Karger

Access to resources Recommend Favorite

Prevalence of Prostate Cancer in End-Stage Renal Disease Patients

By  

Urologia Internationalis, Vol. 80, Iss. 4, 2008-06 ,pp. : 419-424

Karger

Access to resources Recommend Favorite

Hypertension – A Possible Vulnerability Marker for Depression in Patients with End-Stage Renal Disease

By  

Nephron Clin Pract, Vol. 102, Iss. 1, 2005-09 ,pp. : c43-c50

Karger

Access to resources Recommend Favorite

Antibody Response to Hepatitis B Vaccine in End-Stage Renal Disease Patients

By  

Nephron Clin Pract, Vol. 103, Iss. 3, 2006-03 ,pp. : c89-c93

Karger

Access to resources Recommend Favorite